Last year, the Secretary of Health and Human Services (HHS) appointed UCB’s Kristi Lengyel, Director of U.S. Patient Advocacy, to the National Institutes of Health (NIH) Task Force on Research Specific to Pregnant and Lactating Women (PRGLAC). 

CIMZIA® (certolizumab pegol) is the First Therapy to Demonstrate Positive Results in a 52-week, Placebo Controlled Non-Radiographic Axial Spondyloarthritis Study

• BRIVIACT^® (brivaracetam) CV oral formulations are approved as a monotherapy or adjunctive therapy in patients four years of age and older with partial-onset seizures.
• Approval provides pediatric epilepsy patients a treatment option which can be initiated at a therapeutic dose from day one.
• Pediatric epilepsy is the most common, serious neurological disorder among children and young adults, thought to affect nearly 470,000 children in the U.S.,^{1, 2}
• Indication comes less than 2 years after the launch of BRIVIACT in the U.S., building on existing adult monotherapy and adjunctive therapy indications, and broadening clinical application for UCB’s newest anti-epilepsy drug.

By the time you finish reading the title of this post, a fragility fracture due to osteoporosis has occurred. It is estimated that a fragility fracture occurs every 3 seconds— totaling nearly 9 million fractures annually, worldwide. In the U.S. alone, fragility fractures are responsible for approximately 500,000 hospitalizations, 800,000 emergency room visits, and 180,000 nursing home placements each year.

This spring, UCB engaged the Atlanta community at the 2018 Atlanta Science Festival with a booth called “How the Canine Mind Helps People with Severe Diseases.” The festival is a two-week celebration of science offering more than 100 events at locations throughout metro Atlanta. UCB participated at the expo event held in Piedmont Park on March 24. 

Luiz Miguel Camargo, Ph.D., UCB’s Director of Innovation Networks, was featured in an interview as part of the Pharmaceutical Research and Manufacturers of America (PhRMA) #GOBOLDLY campaign talking about his work and dedication to advancing science to find solutions. 

Dr. Victor Sloan, UCB’s VP & Development Strategy Lead (immunology), was featured in an interview as part of the Pharmaceutical Research and Manufacturers of America (PhRMA) #GOBOLDLY campaign. Learn more about Dr. Sloan’s work and his motivation to find groundbreaking solutions.

Today, we announced an exciting addition to UCB’s epilepsy pipeline with an agreement to acquire the rights to Proximagen’s Midazolam Nasal Spray (USL261),¹ an anti-epilepsy drug (AED) developed as an intended rescue treatment for acute repetitive seizures (ARS, also known as serial, recurrent or cluster seizures) in patients with epilepsy.

UCB to expand epilepsy portfolio with strategic acquisition of Midazolam Nasal Spray from Proximagen

April is Parkinson’s Awareness Month. To honor those living with Parkinson’s disease (PD), we’re spreading awareness about the disease and sharing some of our favorite stories of inspiration.